Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 0.89 |
| ▸ | GSK3B | P49841 | 4/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.62 |
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
| ▸ | TYK2 | P29597 | 1/20 | 0.62 |
| ▸ | WNT1 | P04628 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30425762 | 1.00 | ABL1 (0.89) | ABL1GSK3BDYRK1AJAK2TYK2 | |
| SCHEMBL9938850 | 0.94 | ABL1 (1.00) | ABL1 | |
| SCHEMBL19516245 | 0.94 | ABL1 (0.79) | ABL1GSK3BDYRK1AJAK2TYK2 | |
| SCHEMBL19516243 | 0.94 | ABL1 (0.79) | ABL1GSK3BDYRK1AJAK2TYK2 | |
| SCHEMBL30005066 | 0.94 | ABL1 (0.79) | ABL1GSK3BDYRK1AJAK2TYK2 | |
| SCHEMBL19544273 | 0.94 | ABL1 (0.79) | ABL1GSK3BDYRK1AJAK2TYK2 | |
| SCHEMBL19516307 | 0.92 | ABL1 (0.76) | ABL1GSK3BDYRK1AJAK2TYK2 | |
| SCHEMBL30005555 | 0.92 | ABL1 (0.76) | ABL1GSK3BDYRK1AJAK2TYK2 | |
| SCHEMBL19516034 | 0.91 | ABL1 (0.75) | ABL1GSK3BDYRK1AJAK2TYK2 | |
| SCHEMBL19516228 | 0.91 | ABL1 (0.75) | ABL1GSK3BDYRK1AJAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516039-B2 | N-linked isoquinoline amides as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-20240398784-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20230406844-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | disclosed |
| EP-4236950-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022093881-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093881-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-10653688-B2 | 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190125740-A1 | 6-(6-MEMBERED HETEROARYL & ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125740-A1 | 6-(6-MEMBERED HETEROARYL & ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK2, DYRK3 | ABL1 491/4885GSK3B 11/4885DYRK1A 1/4885 |
| US-20230406844-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, BRSK2, CLK2 | ABL1 215/4885GSK3B 229/4885DYRK1A 323/4885 |
| US-20240398784-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, BRSK2 | ABL1 290/4885GSK3B 193/4885DYRK1A 530/4885 |
| US-10653688-B2 | 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK2 | ABL1 562/4885GSK3B 12/4885DYRK1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.